CDKN2A and neoplasm: Molecular markers now incorporated into the WHO CNS5 classification include TERT promoter mutations and CDKN2A/B deletions, which are sufficient to upgrade a tumor to WHO grade lll even in the absence of high-grade histologic features [6,18].